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Abstract
Background: Safety concerns about proprotein convertase subtilisin/kexin type 9 (PCSK9) 
inhibitors make physicians reluctant to prescribe agents for patients. The present aim was to assess 
the efficacy and safety of alirocumab, evolocumab and bococizumab in patients with atherosclerotic
cardiovascular disease (ASCVD).
Methods: Medline, the Cochrane Library and Clinicaltrials.gov were searched for 45 randomized 
controlled trials, involving 97,297 patients. 
Results: Compared with the control group, PCSK9 inhibitors could significantly reduce low-
density lipoprotein cholesterol, total cholesterol, triglycerides and increase high-density lipoprotein 
cholesterol. Alirocumab was associated with lower incidence of unstable angina (p < 0.05) and 
myocardial infarction (p < 0.05), compared with the control group. Alirocumab (odds ratio [OR] 
0.76, 95% confidence interval [CI] 0.60–0.97, p < 0.05), evolocumab (OR 0.79, 95% CI 0.66–0.95, 
p < 0.05) and bococizumab (OR 0.60, 95% CI 0.42–0.84, p < 0.05) were associated with lower 
incidence of stroke, compared with control group. The incidence of injection-site reactions was 
significantly higher in alirocumab (OR 1.68, 95% CI 1.45–1.93, p < 0.05), evolocumab (OR 1.64, 
95% CI 1.41–1.91, p <0.05) and bococizumab (OR 8.03, 95% CI 6.85–9.41, p < 0.05) group than in
the control group. 
Conclusions: Alirocumab and evolocumab could ameliorate lipid profile and reduce the risk of 
cardiac disorders and stroke with satisfactory safety and tolerability. However, injection-site 
reactions should be paid attention to.
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Introduction
Statins were recommended as a first-line therapy for cardiovascular disease (CVD) and 
substantially decreased the risk for CVD events. But, a high proportion of patients did not achieve 
optimal levels of low-density lipoprotein cholesterol (LDL-C) or may have had high residual CVD 
risk despite high-intensity statin therapy. An optional approach is to choose other LDL-C lowering 
agents for these patients on the basis of statins. 
Proprotein convertase subtilisin/kexin type 9 (PCSK9) promotes the degradation of low-density 
lipoprotein receptors (LDLR) at the surface of hepatocytes by binding to LDLR in 
lysosomes/endosomes. PCSK9 inhibitors have emerged as an effective strategy to reduce LDL-C 
and other lipid parameters. Alirocumab and evolocumab appeared to reduce nonfatal major adverse 
cardiac event (MACE) and be well tolerated [1]. But, further development of bococizumab was 
discontinued because of no significant reduction in cardiovascular events and high incidence of 
injection-site reactions with bococizumab [2, 3]. Physicians were still worried about the efficacy 
and safety of PCSK9 inhibitors and reluctant to prescribe for atherosclerotic cardiovascular disease 
(ASCVD) patients. With the increase in evidence in recent years, this meta-analysis was therefore 
performed to evaluate the efficacy and safety of PCSK9 inhibitors (alirocumab, evolocumab, 
bococizumab) currently available in clinical practice.
Methods
Search strategy
This meta-analysis was performed in accordance with the Preferred Reporting of Systematic 
Reviews and Meta-Analysis (PRISMA) statement [4]. Pubmed, the Cochrane Library database, 
Clinicaltrials.gov from March 2012 to March 2021 were searched using the following search items: 
“evolocumab’’, ‘‘AMG 145’’, ‘‘alirocumab’’, “SAR236553”, ‘‘REGN727’’, “bococizumab” and 
“RN316/PF-04950615”. The search pattern is shown in Supplementary Table S2.
Study selection
Two independent investigators screened article titles and full-text according to the inclusion 
criteria. Discrepancies were resolved by discussion and consensus. Risk of bias of was assessed by 
using the Cochrane Risk of Bias tool [5].
No language, follow-up or study size were imposed as restrictions in the searches. Alirocumab, 
evolocumab, bococizumab were all included in the analyses.
Inclusion criteria was set based on the PICOS schema. The PICOS items were as follows: (P) 
patients with hypercholesterolemia or CVD; (I) PCSK9 inhibitors, evaluated the efficacy and safety 
of PCSK9 inhibitors (alirocumab or evolocumab or bococizumab); (C) control, evaluated the 
efficacy and safety of control (placebo or usual care or ezetimibe); (S) randomized controlled trials 
(RCTs). 
The exclusion criteria: abstracts, reviews, and case reports; no report of efficacy and safety 
assessments. 
Data extraction
The following data were extracted: sample size, age, design, follow-up duration, lipid profiles 
(LDL-C, total cholesterol [TC], triglycerides [TG], high-density lipoprotein cholesterol [HDL-C]), 
unstable angina (UA), myocardial infarction (MI), stroke, injection site reaction, myalgia.
Statistical analysis
Review Manager software 5.3 was used to calculate all statistical analyses. I2 statistic were used 
to assess heterogeneity in the analysis. If I2 < 50%, a fixed-effect model was used; otherwise, a 
random-effect model was applied. Publication bias was examined by using the funnel plot. For 
dichotomous data, odds ratios were used. Continuous data (lipid outcomes) were expressed as mean
difference (MD) of percentage change from baseline and 95% confidence interval (CI). P < 0.05 
was considered statistically significant. The risk of bias was estimated by using the parameters: 
sequence generation, concealment of group allocation, blinding during outcome assessment, 
selective reporting and intention-to-treat analysis [6].
Results
Initially, a total of 1820 studies were searched, of which 82 studies were excluded because of 
duplication and 893 studies failed to meet the inclusion criteria. Finally, a total of 45 RCTs 
involving 97,297 patients were included. Of these, 21 RCTs were treated with alirocumab, 21 RCTs 
were treated with evolocumab, and 3 RCTs were treated with bococizumab. The study selection 
flow diagram is shown in Figure 1. Characteristics of the included studies are shown in 
Supplementary Table S1 ([S1–S45]). 
Lipid profile 
Triglycerides, TC, LDL-C, and HDL-C were reported in 42 studies with a total of 92,681 
patients, of which 21 studies were treated with alirocumab, 18 studies were treated with evolocumab
and 3 studies were treated with bococizumab. Compared with control group, alirocumab reduced 
LDL-C by –51.29% (95% CI –55.83 to –46.75, p < 0.05), TC by –30.31% (95% CI –34.26 to –
26.36, p < 0.05), TG by –10.31% (95% CI –13.81 to –6.81, p < 0.05) and increased HDL-C by 
5.63% (95% CI 4.86 to 6.40, p < 0.05). Compared with control group, evolocumab reduced LDL-C 
by –53.99% (95% CI –58.45 to –49.54, p < 0.05), TC by –34.2% (95% CI –36.18 to –32.21, p < 
0.05), TG by –8.86% (95% CI –13.17 to –4.55, p < 0.05) and increased HDL-C by 7.05% (95% CI 
5.55 to 8.54, p < 0.05). Compared with control group, bococizumab reduced LDL-C by –56.96% 
(95% CI –60.69 to –53.23, p < 0.05), TC by –38.96% (95% CI –43.33 to –34.58, p < 0.05), TG by –
17.64% (95% CI –20.79 to –14.48, p < 0.05) and increased HDL-C by 5.98% (95% CI 4.86 to 7.11,
p < 0.05) (Table 1).
Cardiac disorders
Unstable angina and MI were considered as cardiac disorders. UA were reported in 13 studies 
with a total of 57,717 patients, of which 6 studies treated with alirocumab, 4 studies treated with 
evolocumab and 3 studies treated with bococizumab. MI were reported in 16 studies with a total of 
90,355 patients, of which 8 studies treated with alirocumab, 6 studies treated with evolocumab and 
2 studies treated with bococizumab. UA was less common in the alirocumab group (odds ratio [OR]
0.69, 95% CI 0.48 to 0.98, p < 0.05) (Fig. 2A), as was the frequency of MI (OR 0.85, 95% CI 0.76 
to 0.95, p < 0.05) (Fig. 2B). There was no significant difference in the risk of UA between 
evolocumab and control group (OR 0.66, 95% CI 0.42 to 1.03, p > 0.05) (Fig. 2C). However, 
evolocumab was associated with lower risk of MI (OR 0.73, 95% CI 0.65 to 0.82, p < 0.05) (Fig. 
2D). No statistically significant difference in UA (OR 0.82, 95% CI 0.67 to 1.00, p = 0.05) (Fig. 2E)
and MI (OR 0.94, 95% CI 0.78 to 1.14, p > 0.05) (Fig. 2F) was found between bococizumab and 
control.
Stroke
The incidence of stroke was significantly lower in alirocumab (OR 0.76, 95% CI 0.60 to 0.97, p 
< 0.05) (Fig. 3A), evolocumab (OR 0.79, 95% CI 0.66 to 0.95, p < 0.05) (Fig. 3B), and 
bococizumab (OR 0.60, 95% CI 0.42 to 0.84, p < 0.05) (Fig. 3C) group than in control group.
Safety
The safety concerns included injection-site reactions and myalgia. Injection-site reactions 
included dryness, discoloration, erythema, exfoliation, hematoma, hemorrhage, edema, pain, rash, 
sweeling, urticaria, vesicles or bruising at the injection site. The incidence of injection-site reactions
was significantly higher in alirocumab (OR 1.68, 95% CI 1.45 to 1.93, p < 0.05) (Fig. 4A), 
evolocumab (OR 1.64, 95% CI 1.41 to 1.91, p < 0.05) (Fig. 4B), and bococizumab (OR 8.03, 95% 
CI 6.85 to 9.41, p < 0.05) (Fig. 4C) group than in control group. Compared with control group, 
alirocumab (OR 1.18, 95% CI 0.92 to 1.53, p > 0.05) (Fig. 5A), evolocumab (OR 1.09, 95% CI 0.85
to 1.38, p > 0.05) (Fig. 5B), and bococizumab (OR 1.05, 95% CI 0.92 to 1.20, p > 0.05) (Fig. 5C) 
group had no significant difference in the incidence of myalgia.
Discussion
In the current study, it was found that PCSK9 inhibitors could lead to marked reduction in LDL-
C, TC, TG, and increase in HDL-C. Alirocumab, evolocumab and bococizumab could reduce LDL-
C > 50%, increase HDL-C > 5%. PCSK9 inhibitors could ameliorate the lipid profile. The present 
results about lipid changes were consistent with the meta-analysis by Zhang et al. [7].
This meta-analysis has shown that alirocumab and evolocumab probably have beneficial effects 
on cardiovascular outcomes. The current study demonstrated that evolocumab could reduce the 
incidence of MI, but did not have significant benefit with respect to UA. It was considered that this 
result should be interpreted with caution. 
According to available research, this is the first meta-analysis to demonstrate the efficacy and 
safety of bococizumab. Injection-site reactions occurred in 8.4% of patients with bococizumab. 
Meanwhile, the rate of injection-site reactions for alirocumab and evolocumab therapy were 4.5% 
and 2.7%, respectively. Alirocumab, evolocumab and bococizumab had no significant difference in 
the incidence of myalgia. In the current analysis, it was found that bococizumab was not associated 
with reduction of cardiovascular events. These findings observed in the current analysis was similar
to that observed in the SPIRE study [2]. It was thought that this was the reason why the sponsors 
decided to discontinue the clinical development of bococizumab. More RCTs are needed to provide 
more evidence to prove the efficacy and safety of bococizumab.
PCSK9 is expressed in atherosclerotic plaques and might promote atherosclerosis by stimulating 
inflammation and endothelial dysfunction [8]. The present study found that alirocumab and 
evolocumab could reduce the risk of cardiovascular events and stroke, which may be related to their
ability to ameliorate the blood lipid profile, inhibit PCSK9 expression in plaques, and inhibit 
inflammation. These findings were very encouraging and demonstrated conclusive evidence in 
favor of alirocumab and evolocumab therapy for CVD patients with acceptable safety concerns. In 
real-world practice, evolocumab has been prescribed with favorable safety and tolerability 
outcomes [9]. However, more randomized clinical evidence was needed to explore the efficacy of 
bococizumab.
Limitations of the study
There are several limitations that should be taken into account in this analysis. First, the dose of 
PCSK9 inhibitors and different follow-up duration may have affected heterogeneity to the results. 
The shortest follow-up period was 8 weeks, the longest was 134 weeks. Second, the pooling of data 
in control group was a mixture of placebo or ezetimibe. Third, definitions of efficacy and safety 
were nonuniform in the included studies.
Clinical perspective
In our opinion, there is enough evidence with alirocumab and evolocumab on cardiovascular 
events and lipid profile to approve of using them. 
Adverse events of PCSK9 inhibitors were mild and acceptable in patients with CVD. PCSK9 
inhibitors were generally safe and well tolerated.
Conclusions
In conclusion, the present meta-analysis revealed that, compared with no PCSK9 inhibitors 
management, treatment with alirocumab and evolocumab could ameliorate lipid profile in ASCVD 
and reduce the risk of cardiac disorders and stroke. However, injection-site reactions should be paid 
attention to.
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Figure 1. Selection flow diagram. In total, 1820 studies were identified. Finally, 45 studies were 
selected.
Figure 2. Forest plots of cardiac disorders with proprotein convertase subtilisin/kexin type 9 
(PCSK9) inhibitors versus control. The odds ratio (OR) of unstable angina (UA) in alirocumab and 
control group differ significantly (OR 0.69, 95% confidence interval [CI] 0.48 to 0.98, p < 0.05) 
(A). The OR of myocardial infarction (MI) in alirocumab and control group differ significantly (OR
0.85, 95% CI 0.76 to 0.95, p < 0.05) (B). There was no significant difference in the risk of UA 
between evolocumab and control group (OR 0.66, 95% CI 0.42 to 1.03, p > 0.05) (C). Evolocumab 
was associated with lower risk of MI (OR 0.73, 95% CI 0.65 to 0.82, p < 0.05) (D). No statistically 
significant difference in UA (OR 0.82, 95% CI 0.67 to 1.00, p = 0.05) (E) and MI (OR 0.94, 95% CI
0.78 to 1.14, p > 0.05) (F) was found between bococizumab and control.
Figure 3. Forest plots of stroke with proprotein convertase subtilisin/kexin type 9 (PCSK9) 
inhibitors versus control. Stroke were reported in 10 studies with a total of 87,837 patients, of which
4 studies treated with alirocumab, 4 studies treated with evolocumab and 2 studies treated with 
bococizumab. The incidence of stroke was significantly lower in alirocumab (odds ratio [OR] 0.76, 
95% confidence interval [CI] 0.60 to 0.97, p < 0.05) (A), evolocumab (OR 0.79, 95% CI 0.66 to 
0.95, p < 0.05) (B) and bococizumab (OR 0.60, 95% CI 0.42 to 0.84, p < 0.05) (C) group than in 
control group.
Figure 4. Forest plots of injection site reaction with proprotein convertase subtilisin/kexin type 9 
(PCSK9) inhibitors versus control. Injection-site reactions were reported in 38 studies with a total 
of 94,444 patients, of which 19 studies treated with alirocumab, 16 studies treated with evolocumab 
and 3 studies treated with bococizumab. The incidence of injection-site reactions in alirocumab (OR
1.68, 95% CI 1.45 to 1.93, p < 0.05) (A), evolocumab (OR 1.64, 95% CI 1.41 to 1.91, p < 0.05) (B) 
and bococizumab (OR 8.03, 95% CI 6.85 to 9.41, p < 0.05) (C) group was significantly higher than 
in control group.
Figure 5. Forest plots of myalgia with proprotein convertase subtilisin/kexin type 9 (PCSK9) 
inhibitors versus control. Myalgia was reported in 30 studies with a total of 47,128 patients, of 
which 14 studies treated with alirocumab, 13 studies treated with evolocumab and 3 studies treated 
with bococizumab. Compared with control group, alirocumab group (OR 1.18, 95% CI 0.92 to 1.53,
p > 0.05) (A), evolocumab group (OR 1.09, 95% CI 0.85 to 1.38, p > 0.05) (B) and bococizumab 
group (OR 1.05, 95% CI 0.92 to 1.20, p > 0.05) (C) had no significant difference in the incidence of
myalgia. 
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